Should I buy Viatris (VTRS) stock or is it too late?

Viatris · Health Care · price $17

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 66% of its targets hit on this sector (358 calls tested). It aims for $26 (+51 %), call made on October 6, 2026, maturing on October 6, 2027 (8 d ago).

The 5 reliable analysts $20+16 %

The 3 other firms $20+16 %

How to read it: the 5 reliable firms are not filtered by optimism — 4 aim above the price, 1 below, hence their $20 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Viatris

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Barclays	33 %	-9.5 %	6	$22 +28%

In short — Should you invest in Viatris? Is it too late, still worth it? Analysts are fairly positive (75% buy, median target $20, i.e. +16%), and the most reliable on VTRS targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
Median price target $20, i.e. +16% from the current price ($17).
The most reliable firm on VTRS, Barclays (33% hit rate, 6 scored calls), targets $22 (call made on May 19, 2026, maturing on May 19, 2027) (+28%) in its most recent call, and $15 (call made on December 9, 2025, maturing on December 9, 2026) (-13%) in the one coming due soonest.
Pays a dividend (3.0% yield) — regular income on top of potential upside.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 8 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on VTRS

Median target $20 (+16%) · 8 ratings · Buy consensus

Strong Buy00%

Buy675%

Hold225%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Viatris now?

We won't decide for you. The facts: 75% of analysts rate it a buy, median target $20 (+16%), and Barclays (most reliable on VTRS, 33%) targets $22. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Viatris?

Not according to analysts: the median target ($20) is still +16% above the current price ($17) (most reliable on VTRS: Barclays, 33%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Viatris still worth investing in?

It depends on the gap between the price ($17) and its estimated value: analysts target $20 on median (+16%), with 75% buys (most reliable on VTRS: Barclays, 33%). Cross-check with their real reliability on VTRS and the cautions above. Information, not advice.

What's the main risk in buying VTRS?

The consensus is not unanimous: of 8 ratings, 2 are neutral.

→ Go deeper: the full Viatris profile (consensus, analyst reliability, price target, performance).